Evidence map›Paper›PMID 42288045›Full record

ArticleTranslational oncology2026

Real-world evidence of RET fusion prevalence and testing in patients with metastatic non-small cell lung cancer.

B N Cajiao Garcia, V D de Jager, C C H J Epskamp-Kuijpers, A J van der Wekken, S M Willems, L C van Kempen, E Schuuring

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

B N Cajiao GarciaDepartment of Pathology and Medical biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
V D de JagerDepartment of Pathology and Medical biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
C C H J Epskamp-KuijpersFoundation Palga, Houten, the Netherlands.
A J van der WekkenDepartment of Pulmonary Disease and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
S M WillemsDepartment of Pathology and Medical biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
L C van KempenDepartment of Pathology and Medical biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Department of Pathology, University of Antwerp, Antwerp University Hospital, Edegem, Belgium.
E SchuuringDepartment of Pathology and Medical biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: e.schuuring@umcg.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesRearranged during transfection (RET) fusion is a driver aberration in non-small cell lung cancer (NSCLC). Approval of RET inhibitors selpercatinib and pralsetinib prompts adequate molecular testing for RET fusions in NSCLC. The aim of this study was to determine changes in the detection of RET fusions and the effect of various testing strategies in stage IV NSCLC patients using real-world data. MATERIALS AND

methodsPatients diagnosed with metastatic non-squamous NSCLC in 2017 and 2019 were selected from Netherlands Cancer Registry (NCR) database and linked to their pathology reports form the Dutch nationwide pathology databank (Palga). Based on these data, RET fusion testing rates, prevalence and laboratory variation were evaluated.

resultsA total of 3651 patients and 3934 patients were included in 2017 and 2019, respectively. The prevalence of RET fusion in non-squamous NSCLC was 1.3% and 0.7%, in 2017 and 2019, respectively. The overall RET fusion testing rate increased from 22.6% (2017) to 31.8% (2019). Between 2017 and 2019, a shift from FISH (91% to 47%) to RNA-based testing (6% to 46%) for the detection of RET fusions was observed.

conclusionThe prevalence calculated from real-world data in the Netherlands with nation-wide coverage was 1.3% in 2017 and 0.7% in 2019. The decrease in detected RET fusions between 2017 and 2019 was associated with decreased use of FISH testing The prevalence of RET fusions in non-squamous NSCLC published in the literature (1-2%) is therefore likely overestimated.

Indexed as

Non-small cell lung cancerPralsetinibPredictive biomarker testingRET fusionSelpercatinib

Identifiers

PMID42288045
PMCPMC13279202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.